Associated tags: Patient, Tongue, TEP, Helios, Gait, Medical device, Neurology, Pons, Multiple sclerosis, MS, HSDT, Pharmaceutical industry, Therapy, Medical imaging, Brain
Retrieved on:
Wednesday, November 9, 2022
NEWTOWN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the participation of Prue Plummer PhD, PT, Professor in the Department of Physical Therapy in the School of Health and Rehabilitation Sciences at the MGH Institute of Health Professions to its Therapeutic Experience Program (“TEP”). The MGH Institute of Health Professionals joins NYU Langone Health, the Shepherd Center, and Oregon Health & Science University as the fourth Center of Excellence in this company-sponsored open-label observational trial designed to evaluate the impact of subjects’ adherence to Portable Neuromodulation Stimulator (PoNS) therapy in patients with multiple sclerosis (“MS”).
Key Points:
- We are thrilled to have Dr. Plummer and the MGH Institute of Health Professions, one of the countrys preeminent health and rehabilitation institutions, as one of our Centers of Excellence for TEP, said Antonella Favit-Van Pelt, M.D., Ph.D., Helius' Chief Medical Officer.
- The purpose of our Therapeutic Experience Program is to gain insight about the functional outcome of PoNS therapy used with MS by treating patients in a real-world environment.
- We are enthusiastic about Dr. Plummers participation in the study and her contribution to bringing new therapeutic options to MS patients.
- MGH Institute of Health Professions, a member of Mass General Brigham, was founded in 1977 by the Massachusetts General Hospital and counts more than 10,000 alumni.
Retrieved on:
Tuesday, November 8, 2022
GLOBE,
Forward-looking statement,
Northwestern Health Sciences University,
Center,
Rehabilitation,
Nasdaq,
Research,
Education,
Health,
Therapy,
Private Securities Litigation Reform Act,
Sale,
Multiple sclerosis,
Tongue,
Pons,
Neurology,
International Classification of Functioning, Disability and Health,
COVID-19,
Traumatic brain injury,
Helios,
FAAN,
MCR,
Brain,
News,
Securities and Exchange Commission (Philippines),
HSDT,
Excellent,
Gait,
Time,
Internet,
Management of multiple sclerosis,
Oregon Health & Science University,
FANA,
Company,
Contract,
Maintenance,
Medicare,
Patient,
TEP,
OHSU,
MS,
MD,
Regulation,
FDA,
Pharmaceutical industry,
Medical device,
Medical imaging,
Medicaid NEWTOWN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced the addition of Oregon Health & Science University (OHSU) to its Therapeutic Experience Program (TEP).
Key Points:
- NEWTOWN, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced the addition of Oregon Health & Science University (OHSU) to its Therapeutic Experience Program (TEP).
- This initiative will be led by Vijayshree Yadav, MD, MCR, FANA, FAAN, Professor of Neurology and OHSU Multiple Sclerosis Center Director.
- A significant portion of MS patients suffer from gait deficit and PoNS therapy provides a unique opportunity to improve gait functionality and mobility.
- Oregon Health & Science University is Oregon's only academic health center and distinguished nationally as a research university dedicated solely to advancing health sciences.
Retrieved on:
Thursday, November 3, 2022
Therapy,
Physical therapy,
HSDT,
Pons,
Exercise,
MS,
Multiple sclerosis,
GLOBE,
Congress,
Result,
Conference,
Brain,
American Congress of Rehabilitation Medicine,
Helios,
Gait,
Nerve,
Neurology,
NASDAQ,
ACRM,
Tongue,
Goal,
TEP,
American,
Physical medicine and rehabilitation,
Patient,
Pharmaceutical industry,
Medical imaging,
Medical device Visitors to booth 512 will see the device and learn more about how it can improve gait deficiency in people with multiple sclerosis (MS) .
Key Points:
- Visitors to booth 512 will see the device and learn more about how it can improve gait deficiency in people with multiple sclerosis (MS) .
- PoNS works by delivering electrical impulses through nerve fibers on the tongue, stimulating the flow of millions of neural impulses to the brain structures that control gait.
- In addition to seeing the PoNS device in person, booth visitors can speak with key Helius team members, who can answer questions about PoNS and the accompanying PoNS Therapy regimen that maximizes its effectiveness.
- The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait.
Retrieved on:
Tuesday, November 1, 2022
Pons,
TEP,
Gait,
Newsroom,
Helios,
MS,
Patient,
Webcast,
Multiple sclerosis,
Neurology,
Tongue,
Medical device The webcast will be archived under the Newsroom section of the Companys investor relations website.
Key Points:
- The webcast will be archived under the Newsroom section of the Companys investor relations website.
- Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains ability to compensate and promote neuroplasticity, improving the lives of people dealing with neurologic diseases.
- The Companys first commercial product is the Portable Neuromodulation Stimulator (PoNS).
- The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait.
